Evolent Health (NYSE:EVH) Given New $20.00 Price Target at Truist Financial

Evolent Health (NYSE:EVH) had its target price reduced by Truist Financial from $24.00 to $20.00 in a report published on Monday,Benzinga reports. Truist Financial currently has a buy rating on the technology company’s stock.

Several other equities analysts have also recently weighed in on the stock. BTIG Research lowered their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, December 3rd. Stephens downgraded Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $38.00 to $16.00 in a report on Friday, November 8th. Royal Bank of Canada reissued an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a research report on Tuesday, November 12th. KeyCorp began coverage on Evolent Health in a research note on Friday, October 11th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Oppenheimer dropped their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $22.83.

Evolent Health Price Performance

EVH stock opened at $12.37 on Monday. Evolent Health has a one year low of $10.53 and a one year high of $35.00. The firm has a 50-day moving average of $12.69 and a two-hundred day moving average of $20.97. The firm has a market capitalization of $1.44 billion, a PE ratio of -13.59 and a beta of 1.45. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Institutional Investors Weigh In On Evolent Health

Several institutional investors and hedge funds have recently modified their holdings of EVH. Rhumbline Advisers raised its holdings in Evolent Health by 8.3% during the second quarter. Rhumbline Advisers now owns 180,059 shares of the technology company’s stock valued at $3,443,000 after buying an additional 13,867 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Evolent Health by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock valued at $556,000 after acquiring an additional 649 shares in the last quarter. Quest Partners LLC acquired a new stake in Evolent Health in the 2nd quarter worth approximately $87,000. Federated Hermes Inc. bought a new stake in Evolent Health during the second quarter worth approximately $6,273,000. Finally, Dimensional Fund Advisors LP grew its holdings in Evolent Health by 5.4% during the second quarter. Dimensional Fund Advisors LP now owns 2,368,255 shares of the technology company’s stock valued at $45,286,000 after purchasing an additional 121,770 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.